K
Kenneth R. Carson
Researcher at Washington University in St. Louis
Publications - 150
Citations - 6772
Kenneth R. Carson is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Rituximab & Population. The author has an hindex of 33, co-authored 142 publications receiving 5689 citations. Previous affiliations of Kenneth R. Carson include Ohio State University & Northwestern University.
Papers
More filters
Journal ArticleDOI
Obesity and Cancer
TL;DR: The article examines the importance of managing weight to reduce risk for developing cancer and for survival among cancer patients and presents a set of strategies that can be useful to guide clinical advice to patients for whom weight control is an important adjunct to risk management or to improve quality of life and disease-free survival after diagnosis.
Journal ArticleDOI
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
Kenneth R. Carson,Andrew M. Evens,Elizabeth A. Richey,Thomas M. Habermann,Daniele Focosi,John F. Seymour,Jacob P. Laubach,Susie D. Bawn,Leo I. Gordon,Jane N. Winter,Richard R. Furman,Julie M. Vose,Andrew D. Zelenetz,Andrew D. Zelenetz,Ronac Mamtani,Dennis W. Raisch,Gary W. Dorshimer,Steven T. Rosen,Kenji Muro,Numa R. Gottardi-Littell,Robert L. Talley,Oliver Sartor,David Green,Eugene O. Major,Charles L. Bennett,Charles L. Bennett +25 more
TL;DR: Overall, 52 patients with lymphoproliferative disorders, 2 patients with systemic lupus erythematosus, 1 patient with rheumatoid arthritis,1 patient with an idiopathic autoimmune pancytopenia, and 1 patientwith immune thrombocytopenIA developed PML after treatment with rituximab and other agents from 1997 to 2008.
Journal ArticleDOI
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
Thomas J. Smith,Kari Bohlke,Gary H. Lyman,Kenneth R. Carson,Jeffrey Crawford,Scott J. Cross,John M. Goldberg,James Khatcheressian,Natasha B. Leighl,Cheryl L. Perkins,George Somlo,James L. Wade,Antoinette J. Wozniak,James O. Armitage +13 more
TL;DR: Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.
Journal ArticleDOI
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
Kenneth R. Carson,Daniele Focosi,Eugene O. Major,Mario Petrini,Elizabeth A. Richey,Dennis P. West,Charles L. Bennett +6 more
TL;DR: Clinical findings, pathology, epidemiology, basic science, and risk-management issues associated with PML infection developing after treatment with rituximab, natalIZumab, and efalizumab are reviewed.
Journal ArticleDOI
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.
Todd A. Fehniger,Sarah Larson,Kathryn Trinkaus,Marilyn J. Siegel,Amanda F. Cashen,Kristie A. Blum,Timothy S. Fenske,David D. Hurd,Andre Goy,Stephanie Schneider,Catherine R. Keppel,Nina D. Wagner-Johnston,Kenneth R. Carson,Nancy L. Bartlett +13 more
TL;DR: Preliminary evidence of lenalidomide's activity in patients with rel/ref cHL is provided, and therefore exploration of len Khalidomide in combination with other active agents is warranted.